

ASM 2023 MEETING *Journal*

Welcome to the 57th Annual Scientific Meeting of the European Society for Clinical Investigations



It gives me great pleasure to welcome you to the 57th Annual Scientific Meeting of the European Society for Clinical Investigations, which is held in Prague, capital of the Czech Republic, on June 7-9, 2023.

This is the second time we meet face-to-face since the Covid lockdown, and hopefully it will stay this way for the years to come. The few previous years taught us how to communicate via virtual means, and many conferences are now organized with this in mind. Notwithstanding this, one ought to admit that nothing beats personal interactions during conferences, live presentations, discussion, and other means of personal encounter.

As life moves on, new challenges arise that need to be tackled, which, not surprisingly, also include science. It is without question that increasing importance is now placed on science that spans basic research, be it cell biology, biochemistry or molecular biology, and the clinic, which is broadly referred to as biomedical translational research. Traditionally, such research has been based on the 'from bench to bed' principle, i.e. delivering results of basic research to patients for their benefit. Recently, focus has been given to 'targeted' research, which relates to research that encompasses 'from bed to bench, and back to bed'. In other words, we are learning the needs of patients, applying them to our research and bringing the results to the patient for their enhanced benefit. I believe that this principle will be imprinted in a fair few presentations at this ESCI conference.

Talking briefly about the programme of the ESCI meetings, it comprises a number of parallel symposia. Besides the usual suspects, such as mitochondrial biology, cardiology or diabetology to name a few, we included several new symposia since we believe we have strength in these disciplines, which concerns in particular endocrinology, embryonal pathology and reproductive biology. This indicates that the ESCI conferences, while keeping the core symposia, keep developing, taking on board new challenges and reflecting the location where they are held.

This year, we will host several top researchers to deliver their keynote talks. I would like to mention, in particular, Prof Gregg Semenza from John Hopkins University, Nobel Prize Winner for 2019, as well as Prof. Elizabeth Murchison from University of Cambridge. Already by seeing these names, you know that we are here for a real scientific treat.


And of course, it is you, the delegates of the 57th ESCI conference, who will inevitably make this meeting a great success. I do not want to repeat the clichés about exchanges of ideas, starting collaborations, making new friends, et cetera. You know that this is what conferences are about. What is truly exceptional about the ESCI conferences is the breadth of topics covered, and this has been the trademark of these scientific 'get-togethers'.

Lastly, I want to say that Prague, where we will meet, is a city steeped in history with unique charm. Those who have visited Prague will agree with me on this, those who will visit for the first time will be captivated by its historical atmosphere.

Without further ado, I am immensely looking forward this year's ESCI conference, and wish you all wonderful stay, both from a scientific and social point of view!

Jiri Neuzil

KEY NOTE SPEAKER OPENING OF THE ESCI ASM 2023



Gregg L. Semenza, M.D., Ph.D

Dr. Semenza is the C. Michael Armstrong professor of genetic medicine, with appointments in pediatrics, radiation oncology, biological chemistry, medicine, and oncology at the Johns Hopkins University School of Medicine. He serves as founding director of the Vascular Program at the Johns Hopkins Institute for Cell Engineering and founding director of the Armstrong Oxygen Biology Research Center.

Dr. Semenza received an A.B. (in Biology) from Harvard University and M.D. and Ph.D. (in Genetics) degrees from the University of Pennsylvania. He completed pediatrics residency training at Duke University Medical Center and postdoctoral training in medical genetics at Johns Hopkins. He has been a member of the Johns Hopkins faculty since 1990.

Dr. Semenza's lab discovered hypoxia-inducible factor 1 (HIF-1), a transcription factor that controls the expression of thousands of genes in response to changes in oxygen availability, for which he was awarded the 2019 Nobel Prize in Physiology or Medicine. Dr. Semenza has also received the Albert Lasker Basic Medical Research Award (2016), Lefoulon-Delalande Grand Prize from the Institut de France (2012), and the Canada Gairdner International Award (2010). He has authored more than 450 research articles and book chapters, and his work has been cited more than 180,000 times according to Google Scholar.

Dr. Semenza's current research interests include investigating the molecular mechanisms of oxygen homeostasis, the role of HIF-1 in cancer progression, and the development of HIF inhibitors for cancer therapy.



Dear colleagues and friends,

It is my great pleasure to welcome you at the 57th Annual Scientific Meeting of ESCI in one of the most beautiful European cities Prague. I would like to express my gratitude to the local organizer Prof Jiri Neuzil for hosting this year's congress and for his effort putting together great scientific program. I also thank all the symposia organizers for their commitment to contribute to this year's ASM success.

ESCI is honored to have Prof Gregg L. Semenza (Johns Hopkins School of Medicine, Maryland, USA, winner of Nobel Prize in Physiology or Medicine in 2019) opening our congress. We are also proud to host different excellent keynote speakers and outstanding researchers at our meeting. It is also our great pleasure to award this year's "Albert Struyvenberg Medal" to a distinguished cardiovascular researcher Prof Thomas F. Lüscher (Royal Brompton & Harefield Hospital Trust and Imperial College, London, UK and University Zurich, Switzerland).

This year's ASM will not be only a platform for scientific exchanges and networking but will be also the start of a new ESCI era. Indeed, I am very happy to hand over the role of ESCI president to the president-elect Dr Gemma Vilahur, an excellent scientist and leader who I am very confident will take ESCI to even higher levels.

I am very honored for having been given the trust to be the president of ESCI for the 1 transition year. I am very grateful for having worked with a dedicated council for 1 year of great decisions, changes as well as consolidations, which I am happy to share with you in the following lines:

The council has nominated Prof Paulo Oliveira, the past-ESCI president to be a new member of the council of the Trust foundation and as successor of Prof Lina Badimon. On behalf of the ESCI council, I cordially thank Prof Badimon for the years she committed to the society and her important role within the Trust Foundation. We are very honored to have gained Prof Oliveira and are very confident that he will be a real enrichment to the Trust Foundation.

ESCI is very proud to be part of "PAS GRAS: de-risking metabolic, environmental and behavioral determinants of obesity in children, adolescents and young adults", a project that is newly funded by the European Union's Horizon Europa and led by Paulo Oliveira. ESCI will be involved in the education of young researchers by providing regular training activities on obesity and raising awareness on healthy lifestyles.

After long negotiations, we are in the process of renewing our agreements with Wiley as the publisher of our flagship journal the "European Journal of Clinical Investigation, IF. 5,722". We are looking forward further successful years for our journal and would like to use this opportunity to thank the Editor in Chief Dr Hendrik Nathoe and the Deputy editor in chief Dr. Fabrizio Montecucco for their hard work bringing our journal to the next level. I am inviting each of you to consider the EJCI to publish your latest research. Together, let's make our journal an even better one.

I would like to express my gratitude to the members of ESCI council and the Young Research Council for their continuous commitment to ESCI. I am also grateful for the staff of the ESCI Central Office Marliese Greven and Debbie Barneveld for their permanent support and hard work. Last but not least I would like to thank you all, the ESCI family, for your trust and for being part of ESCI. I cordially invite you to join us in the beautiful city of Barcelona in 2024 for the 58th ASM. Updates on the different programs are regularly posted on ESCI's different social media channels so please follow us on facebook (<https://www.facebook.com/esci.eu.nl/>), Instagram (https://www.instagram.com/esci_society/), Tweeter(http://@ESCI_Society) and on LinkedIn (<https://www.linkedin.com/company/european-society-for-clinical-investigation/>) to stay informed. Wishing you all a nice congress and enjoy the city of 100 towers!

Voahanginirina Randriamboavonjy, PhD
ESCI president



JOINING ESCI

Membership of the European Society of Clinical Investigation includes the online subscription to our monthly journal, the European Journal of Clinical Investigation.

Being a member of the European Society of Clinical Investigation you will benefit from:

- A free subscription to our monthly online journal, the European Journal of Clinical Investigation;
- 15% discount on all Wiley-Blackwell books;
- Registration to the annual congresses at the reduced rate for ESCI members.

ESCI membership fee is € 25,00.

You can apply for ESCI membership by using the application form at www.esci.eu.com.

JUNIOR MEMBERSHIP

Any young scientist under the age of 35 is considered a junior member of ESCI.

Junior members receive the online European Journal of Clinical Investigation and have the same financial benefits as full members.

Junior members are not allowed to vote during the Annual Business Meeting and are not eligible for any office.

CORPORATE MEMBERSHIP

Any company, corporation, organisation, or trust can apply for corporate membership in the Society. Applications shall be approved by the Council.

More info and updates on:

www.esci.eu.com

PLENARY SPEAKERS ANNUAL SCIENTIFIC MEETING 2023

André Lacroix, M.D., FCAHS

André Lacroix is Professor in the Endocrine division and department of Medicine at Centre hospitalier de l'Université de Montréal (CHUM)



He served as chief of Endocrine Division and Director of the Endocrinology Training Program of Université de Montréal. He was Chairman of the Department of Medicine from 2002-2008 and Associate Director General for Medical and Academic Affairs at CHUM (2008-2012).

He served as President of the Canadian Society of Endocrinology and Metabolism (2005-2007) and of the International Society of Endocrinology (2016-20). He is currently co-editor of the Adrenal Section of UpToDate and Encyclopedia of Endocrine Diseases. He received the Robert Volpé 2010 award from CSEM and in 2022 The Emeritus Endocrinologist award from the Québec Association of Endocrinologists and Scientific Career Award from the Association of Francophone Physicians of Canada and from CHUM research center. He was elected Fellow of the Canadian Academy of Health Sciences in 2008 and foreign member of the National Academy of Medicine of France in 2016.

His major areas of research include molecular and genetic mechanisms of adrenal tumors and hyperplasias leading to Cushing's syndrome, primary aldosteronism and adrenal tumorigenesis; role of aberrant adrenal hormone receptors in adrenal overfunction; investigation and therapy of Cushing's disease and syndrome, primary aldosteronism, adrenocortical cancer and pheochromocytomas.

Prof Elizabeth Murchison

Elizabeth Murchison is Professor of Comparative Oncology and Genetics at the University of Cambridge, Department of Veterinary Medicine. Her laboratory, the Transmissible Cancer Group, studies the genetics, evolution and host interactions of clonally transmissible cancers in dogs and Tasmanian devils.



Elizabeth grew up in Tasmania, where she loved to catch glimpses of the island's unique wildlife during hikes in the rugged wilderness. She obtained her undergraduate degree from the University of Melbourne, and performed doctoral research at Cold Spring Harbor Laboratory, New York. After a postdoc-

toral fellowship at the Wellcome Sanger Institute, where she sequenced the genome of the Tasmanian devil and its transmissible cancer, she joined the University of Cambridge in 2013.

The Transmissible Cancer Group is supported by competitive grants from Wellcome, the European Molecular Biology Organisation, the Leverhulme Trust and the Save the Tasmanian Devil Appeal. Elizabeth has been the recipient of several awards, notably the Philip Leverhulme Prize (2014) and the Cancer Research UK Future Leaders in Cancer Research Award (2014). She is a keen science communicator and in 2011 she delivered a TED talk entitled "Fighting a Contagious Cancer" which has been translated into 29 languages and viewed by a global audience more than 500,000 times.

Prof. Wolfgang A. Linke

Wolfgang Linke received a doctorate from the University of Halle-Wittenberg (Germany) and three years of postdoctoral training at the University of Washington (Seattle, USA). He was a Research Assistant at the Institute of Physiology, University of Heidelberg (Germany), and spent sabbaticals at the Mayo Clinic Rochester and Columbia University New York. He held professorships at the University of Muenster (Germany) in Molecular Cell Biology and Ruhr University Bochum (Germany) in Cardiovascular Physiology. Since 2017, he is Full Professor, Chair of Physiology, and Executive Director of the Institute of Physiology II at University Medicine Muenster. For the last >15 years, he has also been an Adjunct Professor or Guest Professor at the University Heart Center Goettingen (Germany). He is a Fellow of the International Society for Heart Research, the American Heart Association, the European Society of Cardiology, and Academician of the Goettingen Academy of Sciences (Germany). His main scientific interests include basic and translational research on cardiac and skeletal muscle function, heart failure and cardiomyopathies, with a focus on sarcomere mechanics, signaling, ultrastructure, and maintenance, with a strong translational view. Current research addresses the cellular and molecular basis of myocardial stiffening in heart failure, the pathomechanisms of inherited cardiomyopathies, and length-dependent activation. He is a renowned expert in the biology and mechanical function of titin, the giant myofibrillar protein. His discoveries of the molecular mechanisms and regulation of titin elasticity in health and disease have shaped current views on the pathomechanism of diastolic heart failure and the search for a reversal of pathological cardiac stiffening by pharmaceuticals. He has published other influential papers on the mechanisms of titin-truncation cardiomyopathy, mechanosensing, sarcomeric protein quality control, and developmental changes in cardiomyocyte structure and function, including stem cell-derived cardiomyocyte maturation.



He was a Research Assistant at the Institute of Physiology, University of Heidelberg (Germany), and spent sabbaticals at the Mayo Clinic Rochester and Columbia University New York. He held professorships at the University of Muenster (Germany) in Molecular Cell Biology and Ruhr University Bochum (Germany) in Cardiovascular Physiology. Since 2017, he is Full Professor, Chair of Physiology, and Executive Director of the Institute of Physiology II at University Medicine Muenster. For the last >15 years, he has also been an Adjunct Professor or Guest Professor at the University Heart Center Goettingen (Germany). He is a Fellow of the International Society for Heart Research, the American Heart Association, the European Society of Cardiology, and Academician of the Goettingen Academy of Sciences (Germany). His main scientific interests include basic and translational research on cardiac and skeletal muscle function, heart failure and cardiomyopathies, with a focus on sarcomere mechanics, signaling, ultrastructure, and maintenance, with a strong translational view. Current research addresses the cellular and molecular basis of myocardial stiffening in heart failure, the pathomechanisms of inherited cardiomyopathies, and length-dependent activation. He is a renowned expert in the biology and mechanical function of titin, the giant myofibrillar protein. His discoveries of the molecular mechanisms and regulation of titin elasticity in health and disease have shaped current views on the pathomechanism of diastolic heart failure and the search for a reversal of pathological cardiac stiffening by pharmaceuticals. He has published other influential papers on the mechanisms of titin-truncation cardiomyopathy, mechanosensing, sarcomeric protein quality control, and developmental changes in cardiomyocyte structure and function, including stem cell-derived cardiomyocyte maturation.

Dr Matthew van der Heiden

Matthew Vander Heiden is the Director of the Koch Institute for Integrative Cancer Research and is the Lester Wolfe Professor in



Molecular Biology in the Department of Biology at the Massachusetts Institute of Technology. He is also an Institute Member of the Broad Institute of Harvard and MIT, and an Instructor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School. Dr. Vander Heiden received his MD and PhD degree from the University of Chicago. He also completed clinical training in Internal Medicine and Medical Oncology at the Brigham and Women's Hospital / Dana-Farber Cancer Institute prior to completing a post-doctoral fellowship at Harvard Medical School. His laboratory studies how metabolism is regulated to meet the needs of cells in different physiological situations with a focus on understanding the role of metabolism in cancer.


Matthias Blüher, MD

Matthias Blüher is Professor of Obesity Medicine, Director of the Helmholtz Institute for Metabolism, Obesity and Vasculture research at the Helmholtz Center Munich and the University of Leipzig, Germany. He is Speaker of the Collaborative Research Center "Obesity mechanisms" at the University of Leipzig in Leipzig, Germany. Matthias Blüher's research is focused on the role of adipose tissue function and distribution in insulin resistance, the development of obesity, type 2 diabetes and other metabolic and cardiovascular diseases.



Professor Blüher completed his medical studies at the University of Leipzig and his postdoctoral fellowship at the Joslin Diabetes Centre, Boston, USA. Matthias' work has been recognized both nationally and internationally, as he is a recipient of the Obesity Research Award of the German Obesity Society 2003, the Ferdinand-Bertram-Prize of the German Diabetes Association 2008, the European Association for the Study of Diabetes (EASD) Rising Star Award (2010), and the Minkowski Prize of the EASD 2015.

BIO ART WINNERS 2023




1st PRIZE

Sarajo Mohanta

Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-University (LMU) Munich

A new coalition in the blood vessel




2nd PRIZE

Celia Gomes

FMUC Coimbra Portugal

The Circle of Life



3rd PRIZE

Taras Zadvornyi

R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of National Academy of Science of Ukraine, Kyiv

Collagen fiber organization in breast cancer tissues



Best 2023 articles published in the European Journal of Clinical Investigation.

2023 ESCI Award for the Best Clinical Research Article

Adrian Post - The Netherlands



Adrian Post was born and raised in Emmen, a small city in the north of the Netherlands. After middle school, he moved to Groningen to study Pharmacy at the Rijksuniversiteit Groningen. After finishing the master Pharmacy, he started studying Medicine, from which graduated he graduated in 2021. Since 2019, he has been working as a PhD-candidate at the Nephrology department of the University Medical Centre Groningen, focusing on lifestyle and nutrition in hemodialysis patients and kidney transplant recipients, as well as many other interesting topics, including non-alcoholic fatty liver disease. The PhD is currently in the final phase and scheduled to finish this year. Furthermore, since 2022, he has been working as a clinical assessor at the Dutch Medicine Evaluation Board, also serving as a clinical expert at the European Medicine Agency.

Adrian Post was born and raised in Emmen, a small city in the north of the Netherlands. After middle school, he moved to Groningen to study Pharmacy at the Rijksuniversiteit Groningen. After finishing the master Pharmacy, he started studying Medicine, from which graduated he graduated in 2021. Since 2019, he has been working as a PhD-candidate at the Nephrology department of the University Medical Centre Groningen, focusing on lifestyle and nutrition in hemodialysis patients and kidney transplant recipients, as well as many other interesting topics, including non-alcoholic fatty liver disease. The PhD is currently in the final phase and scheduled to finish this year. Furthermore, since 2022, he has been working as a clinical assessor at the Dutch Medicine Evaluation Board, also serving as a clinical expert at the European Medicine Agency.

2023 ESCI Award for the Best Basic/Translational Research Article

Michał Ząbczyk - Krakow



Article "Fibrinogen β chain and FXIII polymorphisms affect fibrin clot properties in acute pulmonary embolism"

BIO: Michał Ząbczyk, PhD, medical analyst. Author and co-author of over 100 scientific

papers in the field of blood coagulation, including fibrin clot properties. A principal investigator of several grants from the Polish National Science Centre. Beneficiary of many awards and distinctions for outstanding scientific achievements, including an award from the Polish Ministry of Science and Higher Education.

2023 ESCI Award for the Best Covid-19 Research Article

Sabrina Pagano - Switzerland



Sabrina Pagano studied Biological Sciences with Biotechnology specialization at the University "La Sapienza" of Rome (Italy). She received her PhD title in "Endocrinology and Molecular Medicine" from the Medical

Faculty of the University "La Sapienza" of Rome. After a short postdoctoral fellowship at the Menarini Biotech pharmaceutical company in Italy, she joined the group of Professor Nicolas Vuilleumier in 2008 at the Laboratory Medicine Division at the Diagnostics Department of the Geneva University Hospital (Switzerland) where she is currently head of the research lab.

Her research focus is to investigate the role of the humoral autoimmunity in cardiovascular disease with a particular attention to the study of autoantibodies directed against anti-apolipoprotein A-1, the major protein fraction of HDL, as a biomarker and mediator of atherogenesis.

Winner 2023 Young Investigator Award for excellence in Basic/Translational Research

Christina Garcia Caceres - Germany



Prof. Dr. Garcia-Caceres is a W2 professor at the Ludwig Maximilian University of Munich and serves as the Associate Director and Head of the Astrocyte-Neuron Network Unit at the Institute for Diabetes and

Obesity at Helmholtz Munich (Germany). Professor Dr. Garcia-Caceres has dedicated over 16 years to exploring the molecular basis of obesity pathogenesis and the brain's crucial role in regulating metabolism. Her groundbreaking work, recognized with an ERC Starting Grant, has demonstrated that the brain's control of energy and glucose metabolism goes beyond specific neurocircuits and involves astrocytes. She has also uncovered the previously unrecognized significance of hypothalamic astrocytes in the development of obesity-associated hypertension. Furthermore, her recent research expands beyond astrocytes and delves into understanding how the brain integrates peripheral endocrine cues into hypothalamic circuits. This investigation is critical for comprehending metabolic adaptation in diet-induced obesity. Overall, Professor Dr. Garcia-Caceres's discoveries challenge the traditional neuroendocrine model of obesity treatment and underscore the importance of considering sex as a biological variable in addressing this health issue.

Winner 2023 Young Investigator Award for excellence in Basic/Translational Research

Daniel Kotlarz PhD - Germany



Daniel Kotlarz is a clinician-scientist focusing on translational research directed towards the ultimate goal of improving diagnosis and therapies for children with life-threatening very early onset inflammatory bowel diseases (VEO-IBD). In collaboration with

Prof. Christoph Klein (Head of the Dr. von Hauner Children's Hospital, LMU Munich) he is coordinating the translational research activities of the international VEO-IBD Consortium at the site of the LMU Munich. With the support of a large global collaboration network, he has made major contributions to the field of intestinal inflammation by characterizing patients with CASP8, IL10R, IL21R, LY96, RIPK1, and TGFB1 deficiencies. His studies have been published in the renowned journals Gastroenterology, The Journal of Allergy and Clinical Immunology, Nature Genetics, PNAS, The Journal of Experimental Medicine, and The New England Journal of Medicine. Furthermore, his translational genomic research has been recognized by several awards, including the Innovation Prize 2015 (German University Hospital Association), John Harries Prize 2019 (European Society of Paediatric Gastroenterology, Hepatology and Nutrition), Heinz Maier-Leibnitz-Prize 2020 (DFG and BMBF), and the ECCO Pioneer Award 2023 (European Crohn's and Colitis Organisation).

*Free access
to Abstracts for ESCI 2023 has been
published on Wiley Online Library.*

*Please see below link for reference.
<https://onlinelibrary.wiley.com/toc/13652362/2023/53/S1>*



ESCI - Annual Scientific Meeting

SOCIAL NETWORKING DINER PARTY

Food and drinks at a spectacular location.
Don't miss our social event at Villa Richter.

JUNE 8 - 18:30 DEPARTURE FROM LOBBY

(walking 10 min) (when you are not comfortable walking, please visit the ESCI Desk).



ESCI
EUROPEAN SOCIETY FOR
CLINICAL INVESTIGATION

University of Coimbra leads project funded by the European Commission with 9.5 million euros to fight obesity and promote health throughout life



The project "PAS GRAS: de-risking metabolic, environmental and behavioral determinants of obesity in children, adolescents and young adults", led by the researcher and vice-president of the Center for Neuroscience and Cell Biology of the University of Coimbra (CNC-UC), Paulo Oliveira, has just received 9.5 million euros from Horizon Europe. "PAS GRAS" involves partners from 8 European countries and aims to develop interdisciplinary research and innovation strategies over a five-year period that can change the paradigm of obesity prevention and treatment, providing practical solutions for a healthy life in contemporary society.

The research will clarify the roles of lifestyle, mental health, family history, socioeconomic factors and the environment in the development of obesity, and their interaction with the genetic and metabo-

lic characteristics of each individual. Based on an integrated analysis of multiple parameters, it will be possible to develop a personalized and robust assessment of the increased risk of obesity and associated complications, which include, for example, cardiovascular problems. The study will target children (3-9 years old), adolescents (10-18 years old), young adults (19-25 years old), and their families, who are overweight or obese. Additionally, the project will study cellular and molecular mechanisms underlying the protective effects of Mediterranean diet components and physical activity. Furthermore, it will create an international campaign aimed at increasing health literacy and raising awareness in society about the risks of obesity.

«PAS GRAS will fill critical gaps in the diagnosis and prognosis of obesity and provide a set of innovative tools and measures that can contribute to adopting and maintaining lifestyle choices that counteract overweight/obesity», explains the project leader. Paulo Oliveira further adds that «PAS GRAS is one of the 6 projects funded at the European level. The project has a unique team, involving not only citizens, researchers, health professionals and entrepreneurs, but also

local authorities, and national and international authorities, so that together we can reverse the upward obesity curve, especially in the younger populations».

The project will involve the participation of 15 entities, including Associação de Ginástica do Centro (Portugal), the Associação Protectora Dos Diabéticos De Portugal (Portugal), the Consiglio Nazionale Delle Ricerche (Italy), the European Society for Clinical Investigation (Netherlands), the Fundación EURECAT (Spain), the Instituto Pedro Nunes (Portugal), the Instituto Politécnico De Viana De Castelo (Portugal), Instytut Biologii Doswiadczalnej Im. M. Nenckiego (Poland), the King's College London (United Kingdom), the Martin-Luther-Universität Halle-Wittenberg (Germany), the Mediagnost (Germany), the Technische Universität München (Germany), the Universidade Nova de Lisboa (Portugal), the Università Degli Studi Di Bari Aldo Moro (Italy) and Uppsala Universitet (Sweden).

The "PAS GRAS" project is coordinated by the consortium Center for Innovative Biomedicine and Biotechnology (CIBB), which is formed by CNC-UC, the Coimbra Institute for Clinical and Biomedical Research (iCBR) and the Center for Health Studies and Research at the University of Coimbra (CEISUC). Carolina Caetano and Catarina Ribeiro

This project has received funding from the European Union's Horizon Europe under grant agreement No 101080329



Funded by the European Union

Meet the new President Elect who will be ESCI president from 2023-2027

Dear ESCI members,
Let me briefly introduce myself.

I am currently working as a group Leader at the Research Institute of the Hospital de la Santa Creu i Sant Pau in Barcelona, Spain, where I focus my research on the basic and translational aspects of ischemic cardiovascular disease. I have been the principal investigator of multiple research projects (National and European projects either funded by public agencies or industry), which have allowed me to advance in the knowledge of ischemic heart disease, from atherosclerosis and its cardiovascular risk factors to thrombosis, acute myocardial infarction, and the identification of new therapeutic targets and strategies to prevent and treat ischemic heart disease (>290 publications in WoS; >180 publications in PubMed; H-index: 46; author of 4 patents and founder of 3 spin-offs).

International and national scientific societies have awarded our work. I have received the L'Oreal-UNESCO foundation-for Women in Science Award (2012) and the Outstanding Achievement Award from the European Society of Cardiology (2019). In previous positions of trust, I served as Chair of the Working Group on Thrombosis of the European Society of Cardiology (ESC; 2020-2022), Councilor of the Basic

Cardiovascular Science of the ESC (2018-2022), Board Member of the National Funding Agency (Biomedical area) from the Spanish Ministry of Health (2018-2020) and the Spanish Ministry of Science and Innovation (2021-2024) and have chaired Prestigious Scientific Meetings and Courses.


I am very excited and feel honoured to be stepping into this ESCI leadership position surrounded by a strong and supportive team of Council members that, in collaboration with the ESCI Young Research Councilors, we will work together to build upon our mission to advance medical practice through science by fostering high standards of ethical practice and international cooperation among and through its members.

I do not intend to make drastic changes given ESCI's upward trajectory, and I am fully aware of the work of my predecessors who paved the way for increasing the prestige of the Society and its associated Journal, the European Journal for Clinical Investigation. Building on their excellent work and taking advantage of my previous experience, I look forward to continuing ESCI's progression and also wish to incorporate new ideas, with the full collaboration and agreement of the Councilors, aimed to foster ESCI membership and growth and help to move our initiatives forward over my four-year term.



I do not want to conclude without deeply thanking and congratulating the ASM Local Organizer Jiri Neuzil, our current ESCI President Dr Voahanginirina Randriamboavonjy, and all the excellent Symposium organizers for their tremendous work in preparing such a terrific program with diverse array of topics and an exciting and outstanding slate of speakers which offers unique opportunities for learning and networking. It is my privilege and pleasure to welcome you to our 57th Annual Scientific Meeting and I deeply wish you a successful and enjoyable meeting in Prague.

Dr. Gemma Vilahur
ESCI President 2023-2027



ESCI

EUROPEAN SOCIETY FOR
CLINICAL INVESTIGATION



SEE YOU NEXT YEAR AT THE 58th ESCI ANNUAL SCIENTIFIC MEETING JUNE 5-7, 2024 - BARCELONA, SPAIN

Symposia: mitochondrial biology, hepatology, cardiology, diabetology, metabolic syndrome, big data and bioinformatics, gender medicine, endocrinology

www.esci.eu.com

TECHNICAL SECRETARIAT - ESCI Central Office
Bolognalaan 34 - 3584 CJ Utrecht, The Netherlands. email: esci@umcutrecht.nl